ZSCAN22

Across TCGA pan-cancer cohorts, ZSCAN22 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of ZSCAN22’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where ZSCAN22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZSCAN22 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

BLCA, LIHC, and HNSC are the cancer types where ZSCAN22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZSCAN22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.496	<.001	10	view →
LIHC	Male	II,III,IV	+0.831	<.001	9	view →
HNSC	All	All	+0.331	<.001	9	view →
KIRC	All	All	+0.297	<.001	9	view →
THCA	All	All	−0.217	<.001	8	view →
READ	Male	All	+0.723	.006	6	view →
COAD	Female	All	+0.349	<.001	6	view →
BRCA	All	II,III,IV	+0.271	<.001	6	view →
KICH	All	All	−0.440	<.001	4	view →
CHOL	Male	All	+0.861	<.001	3	view →
STAD	All	II,III,IV	+0.351	.016	3	view →
KIRP	All	IV	+0.719	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

ZSCAN22–BLCA

Open the BLCA breakdown →